Clinical Trial/ tisotumab vedotin

Trial Description

The single arm, multicenter Phase II study (GCT1015-04) of tisotumab vedotin monotherapy is expected to enroll about 100 patients with recurrent or metastatic cervical cancer who have experienced disease progression on or after platinum containing chemotherapy and who have received or are ineligible for bevacizumab.

The primary endpoint of the study is overall response rate (ORR) as assessed by independent review of RECIST v1.1 criteria. The main secondary endpoints are duration of response (DoR) and safety.

This trial is sponsored by Seattle Genetics ®.

Study Data

  • Condition:  Recurrent or metastatic cervical cancer
  • Interventions:
    • Drugs used in this trial
      • tisotumab vedotin
  • Phase: II
  • Enrollment: ~100
  • Start: Enrollment begins in the first half of 2018
  • Estimated Completion: Not yet verified
  • Last verified: October 2017

Study Schematic

Click here to Return to Drug map